Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT03560960 Not yet recruiting - Alzheimer Disease Clinical Trials

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

DTAD
Start date: July 2018
Phase: Early Phase 1
Study type: Interventional

In this multi-center study, the investigators plan to develop a simple blood-based test for early detection of Alzheimer's disease (AD). The test is based on a single injection of Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of diabetes. The investigative team has provided evidence in humans with full-blown AD and AD-relevant mouse models that a single injection of Pramlintide transiently renders the blood brain barrier (BBB) more permeable to Amyloidbeta (Aß) peptides, allowing their efflux from the brain compartment into the blood. This Aß efflux causes a corresponding transient elevation of blood levels of Aß, the magnitude of which the applicants believe is proportional to the brain amyloid load as determined by AV-45 PET. The measured difference in the level of plasma Aß taken just before and a short time after injection should reveal the magnitude of the transient increase in blood Aß levels. Supportive preliminary data comes from later stage (full-blown) AD patients with more in-depth background studies in Tg2576 and 5X Familial Alzheimer's Disease (FAD) mouse models. If successful for use as an early AD (i.e., at the Mild Cognitive Impairment [MCI] stage) biomarker, this could be a game-changer for both early AD diagnostics and clinical trials aimed at identifying and testing the efficacy of drugs useful for treatment of AD at early stages. If Pramlintide is effective in releasing mobile pools of Aß from the brain into the blood, this could also have some therapeutic potential, with the goal of reducing brain amyloid load. Three groups of particpants will be studied: 1) amnestic MCI with or without positive AD imaging pathology, 2) probable AD with positive imaging AD pathology, and 3) controls who have normal cognition and do not have memory complaints.

NCT ID: NCT03560245 Not yet recruiting - Alzheimer Disease Clinical Trials

A Phase 2 Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not receiving memantine treatment. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug. Subjects will receive 7 doses of study drug during the study. The primary efficacy endpoint is change in the Severe Impairment Battery (SIB) scale score after 12 weeks of treatment from baseline (taking the change in the average of SIB measures observed during the Week 13 to Week 15 time window from SIB at baseline.

NCT ID: NCT03556280 Recruiting - Alzheimer Disease Clinical Trials

Multi-Center Study of Sensory Stimulation to Improve Brain Function

Overture
Start date: April 24, 2018
Phase: N/A
Study type: Interventional

The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.

NCT ID: NCT03554226 Active, not recruiting - Alzheimer Disease Clinical Trials

Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study

A3C
Start date: November 1, 2014
Phase: N/A
Study type: Interventional

General Hypothesis: hypothesize that A / A symptoms of AD follow a particular course, influenced by associated factors, and a prospective longitudinal observational study specifically evaluating A / A symptoms in patients with MA, living in an institution and at home, would provide useful data for both clinical practice and research. Specific Hypothesis: hypothesize that in patients with AD with clinically significant A / A there is a correlation between assessment of A / A severity based on specific scales of A / A and overall impression assessment of clinical improvement or worsening of these symptoms by the clinician.

NCT ID: NCT03551769 Not yet recruiting - Alzheimer Disease Clinical Trials

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

Start date: July 19, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase I, single center, open label, fixed-order, crossover, food-effect, pharmacokinetic (PK) study recruiting healthy, adult, male subjects.

NCT ID: NCT03550131 Not yet recruiting - Alzheimer Disease Clinical Trials

Innovations in Dementia Empowerment and Action

IDEA
Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem. Caregiving of sexual/gender minority older adults with AD/RD is of concern due to social stigma, marginalization, and isolation, which may be barriers to sustaining caregiving. It is necessary and timely to translate evidence-based culturally adaptable interventions for this underserved and stigmatized population. Reducing Disability in Alzheimer's Disease (RDAD) has been evaluated in a randomized controlled trial and has shown to successfully train community-dwelling CR (care receiver)-CG dyads to increase the physical activity and functioning of individuals with AD/RD and their CGs and to teach CGs techniques for managing behavioral symptoms of CRs. RDAD consequently decreases stress of CGs, delays institutionalization of CRs, and increases health related quality of life (HRQOL) of CRs and CGs. Thus, this study will evaluate the effect of the standard RDAD among lesbian, gay, bisexual, and transgender (LGBT) CRs with AD/RD and their CGs, and this study will test a personalized intervention tailored to better respond to distinct risks experienced by CGs and LGBT CRs with AD/RD, addressing unique sexual/gender minority CG risk factors (e.g., identity management, stigma-related adverse or traumatic life events, and lack of social support).

NCT ID: NCT03549078 Recruiting - Clinical trials for Compensation Strategies

A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

This intervention is designed to promote enhanced use of compensation strategies including calendar and task list use, and organization systems, as well as increased engagement with brain health activities including physical exercise, cognitive activities, and stress reduction.

NCT ID: NCT03548883 Enrolling by invitation - Clinical trials for Alzheimer Disease, Early-Onset

Examining Neuroinflammation in AlzHeimer's

ENHANCE
Start date: June 2016
Phase:
Study type: Observational

Alzheimer disease (AD) is a neurodegenerative disorder with a poorly understood pathology. It is an irreversible progressive brain disease that slowly deteriorates memory, thinking and behavior. It affects the elderly population and is also hereditary. The incidence doubles with every decade after sixty with no signs of leveling off. More than 35 million people Worldwide, including 5.5 million living in the United States, suffer from AD. As the United States population ages, it is expected that the number of people with AD will increase, reaching 13.2 to 16.0 million by the year 2050. The cost of care for patients with AD in the United States is expected to rise as well, from $172 billion a year in 2010 to a trillion dollars a year by 2050. Although the exact etiopathology is not known there are several lines of evidence that suggest that metabolic and inflammatory features are important. It also has been known for many years that the Blood Brain Barrier (BBB) of Alzheimer's patients allow more harmful particles to cross into the brain than the BBBs of those without the disease do. It's known that this barrier, which is regulating transfer of molecules between the brain and blood, and vice versa blood and brain, can become leaky and dysfunctional (in particular capillaries dysfunction) and lead to subsequent problems likely contributing to onset and progression of dementia. This protocol will explore several of the most promising putative factors that cause AD.

NCT ID: NCT03548584 Recruiting - Alzheimer Dementia Clinical Trials

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Start date: May 16, 2018
Phase: Phase 3
Study type: Interventional

This study compares the efficacy of 2 doses of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type.

NCT ID: NCT03545789 Recruiting - Healthy Volunteers Clinical Trials

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

Start date: March 12, 2018
Phase: Phase 1
Study type: Interventional

The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.